Get the Stockscreener App
3.08
5.00%
-0.12
After Hours:
3.10
0.02
+0.65%
Cellectar Biosciences Inc stock is traded at $3.08, with a volume of 180.63K.
It is down -5.00% in the last 24 hours and up +10.14% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$3.20
Open:
$3.16
24h Volume:
180.63K
Relative Volume:
0.19
Market Cap:
$24.85M
Revenue:
-
Net Income/Loss:
$-21.79M
P/E Ratio:
-0.4981
EPS:
-6.1838
Net Cash Flow:
$-23.12M
1W Performance:
-0.65%
1M Performance:
+10.14%
6M Performance:
-11.88%
1Y Performance:
+1,120%
1-Day Range:
$3.02
$3.29
1-Week Range:
$2.97
$3.29
52-Week Range:
$0.241
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.11 | 25.57M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Maxim Group | Hold → Buy |
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
View All
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan
Cellectar Biosciences Announces Board Changes and New Director - TipRanks
Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan
Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView
Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan
User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN
CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing - Minichart
Cellectar Biosciences, Inc.Common Stock (NQ: CLRB - FinancialContent
What's Going With Cellectar Biosciences Stock On Wednesday? - MSN
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Cellectar Biosciences Signals Pivotal Turn in Earnings Call - TipRanks
Cellectar Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing - GuruFocus
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 - MSN
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress - Investing.com UK
Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202 - GuruFocus
Cellectar Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress By Investing.com - Investing.com Nigeria
CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum - TradingView
Cellectar (CLRB) Secures $140 Million Financing for Regulatory M - GuruFocus
Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call - Benzinga
Cellectar Biosciences 1Q Loss $5.65M >CLRB - Moomoo
CLRB: Strong efficacy in r/r WM and robust financing position clinical programs for key milestones - TradingView
Cellectar Biosciences reports Q1 2026 net loss of $5.65M; cash $8.3M before $31M financing - TradingView
Cellectar Biosciences (CLRB) posts Q1 2026 loss and secures up to $140M - Stock Titan
Cellectar Biosciences, Inc. Q1 2026: Net loss $(5.65M), EPS $(1.33) — 10-Q Summary - TradingView
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cellectar Biosciences (NASDAQ: CLRB) posts Q1 loss and flags going-concern risk - Stock Titan
CLRB: Net loss narrowed, clinical data for iopofosine I 131 remained strong, and $35M was raised for Phase 3 - TradingView
Cellectar Biosciences Inc expected to post a loss of $1.88 a shareEarnings Preview - TradingView
Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock - Investing.com UK
Cellectar Biosciences CEO buys $24,998 in company stock - Investing.com UK
Cellectar Biosciences CEO buys $24,998 in company stock By Investing.com - Investing.com South Africa
Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock By Investing.com - Investing.com Canada
Cellectar (NASDAQ: CLRB) COO boosts stake with common stock and warrant buys - Stock Titan
Cellectar (CLRB) CEO reports open-market stock and warrant buys - Stock Titan
Stonepine, Jon Plexico disclosed 9.9% stake in Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 - Investing News Network
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cellectar Biosciences Inc Stock (CLRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
May 07 '26 |
Buy |
2.88 |
8,680 |
24,998 |
20,318 |
| NEIS JOHN | Director |
Dec 12 '25 |
Sale |
3.70 |
198 |
732 |
10 |
| CARUSO JAMES V | Chief Executive Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
11,638 |
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):